Darlene Dobkowski, MA

This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.

Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid tumors with RET mutations.

Using an artificial intelligence-based navigation tool to contact patients who missed their colonoscopy appointment may help them reschedule and potentially attend a new appointment.

Converting operating rooms into those that are able to filter surgical smoke and biological contaminants can make workplaces safer for nurses and other health care staff.

Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.

Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were treated with 2 or more prior lines of systemic therapy.

Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.

The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.

In this episode of The Vitals, we speak with an expert who discussed the importance of supportive care and education for patients with lung cancer who are treated with immunotherapy.

The role of a verification nurse can lead to several benefits, including the prevention of errors from reaching the patient, decreased workload, and potential cost savings from less drug waste.

Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.

A feasibility study on the use of a mobile application for patients after undergoing a stem cell transplant may help care teams quickly identify and treat graft-versus-host disease.

Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.

Over 500 attendees at this in-person event celebrated the incredible efforts made by oncology nurses when caring for patients with cancer.

An expert discussed a screening tool that she and her colleagues used to connect patients with cancer to palliative care services in a more effective way.

Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Nogapendekin alfa inbakicept-pmln has been approved for use with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

One expert explains the importance of deciphering the data obtained through wearable technology while aiming to avoid data fatigue in oncology nurses.

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

Discussions at a Community Case Forum event emphasized the importance of listening to patient concerns and a multidisciplinary approach when treating advanced endometrial cancer.

Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Amanda Duck, PA-C, RD, held a discussion during a Community Case Forum on the progress made in using immunotherapy to treat patients with advanced endometrial cancer and the creativity sometimes needed to address adverse events.

Accelerated approval was granted by the FDA to ponatinib plus chemo for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

An expert explained the importance of having strong communication skills not only for all patients with cancer, but especially for those who received a terminal diagnosis.

The FDA approved zanubrutinib plus obinutuzumab for the treatment of patients with relapsed or refractory follicular lymphoma after receiving 2 or more lines of systemic therapy.

Nivolumab plus cisplatin and gemcitabine received FDA approval for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

An oncology nurse and pharmacist discuss the multidisciplinary approach to administering TIL therapy in patients with advanced melanoma.

Even though wearable technology can track symptoms and physical activity, among other information, in patients with cancer, more research is needed to determine how it all can benefit the management of these patients by oncology nurses.